...
首页> 外文期刊>Current pharmaceutical design >Metabolic syndrome and non-cardiac vascular diseases: An update from human studies
【24h】

Metabolic syndrome and non-cardiac vascular diseases: An update from human studies

机译:代谢综合征和非心血管疾病:人类研究的更新

获取原文
获取原文并翻译 | 示例
           

摘要

The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition. Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, uric acid, liver function, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, polycystic ovary syndrome and obstructive sleep apnea. Apart from CVD and T2DM, MetS has been related to non-cardiac vascular diseases and in particular to stroke, carotid artery disease, peripheral artery disease, chronic kidney disease, atherosclerotic renal artery stenosis and abdominal aortic aneurysms. In this narrative review, the associations of these diseases with MetS and its components will be discussed. These associations may further increase CVD risk in MetS patients, highlighting the importance of treating such high-risk individuals early and "to target". In this context, multifactorial treatment including a statin has been proven beneficial, and thus should be considered, in MetS patients.
机译:代谢综合征(METS)的特点是危险因素,包括中央肥胖,高血压,血脂血症和胰岛素抗性,该科得到的心血管疾病(CVD)的风险增加,以及2型糖尿病(T2DM)的风险增加。几家国际组织使用不同的诊断标准定义了METS,这些标准产生了先前研究结果的差异,从而导致最新的联合临时社会(JIS)METS定义。与已与Mets相关的诊断标准的其他风险因素包括脂质异常,尿酸,肝功能,普癌细胞因子,细胞因子,adipokines,维生素D,动脉僵硬,多囊卵巢综合征和阻塞性睡眠呼吸暂停。除了CVD和T2DM外,Mets已经与非心脏血管疾病有关,特别是中风,颈动脉疾病,外周血动脉疾病,慢性肾病,动脉粥样硬化肾动脉狭窄和腹主动脉瘤。在这一叙述审查中,将讨论这些疾病与大会及其组成部分的协会。这些关联可能进一步提高Metss患者的CVD风险,突出了治疗此类高危人员早期和“目标”的重要性。在这种情况下,已被证明包括他汀类药物的多因素治疗有益,因此应该考虑在Mets患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号